This second round of funding raises the equivalent of $45.4 million to support the advancement of Oxford-based Evox’s exosome-based therapeutics pipeline, including pushing several rare disease ...

This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Sterol 14 Alpha-Demethylase Inhibitor development. The report ...

Eli Lilly has announced a central nervous system research tie-up with UK biotech Evox Therapeutics, which focuses on drug engineering using vesicles to deliver drugs to targets. These tiny ...

Fate Therapeutics FATE reported a loss of 32 cents ... Its immuno-oncology pipeline includes iPSC-derived natural killer (NK) cells and T-cell product candidates. A phase I study of FT819, a ...

SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and ...

ATLANTA, May 5, 2025 /PRNewswire/ -- Odylia Therapeutics, a nonprofit (501(c)3) biotechnology company dedicated to advancing treatments for rare diseases, today announced its latest pipeline ...

Eli Lilly is expanding its efforts to advance next-generation pain medications. | Eli Lilly is expanding its efforts to ...

Four months after Vertex Pharmaceuticals Inc.’s U.S. FDA nod for Journavx (suzetrigine) as the first drug targeting NaV1.8 for treating pain, Eli Lilly and Co. is joining the potential competition via ...

ATLANTA, May 5, 2025 /PRNewswire/ -- Odylia Therapeutics, a nonprofit (501(c)3) biotechnology company dedicated to advancing treatments for rare diseases, today announced its latest pipeline project: ...

Palvella Therapeutics (NASDAQ: PVLA) presented its Q1 2025 financial results and corporate update on May 15, 2025, highlighting progress in its rare disease pipeline and strong financial footing.